269 results about "Vasculitis" patented technology

Disclosed herein are methods for treating a vascular inflammatory disorder or endothelial cell disorder using inhibitor compounds that inhibit the expression or biological activity of Tie-1, Tie-1 endodomain, thrombin, VEGFR2, VEGFR2 endodomain, EphA2, and any of the cytokines or kinases that are upregulated by activation of Tie-1 or thrombin, as provided herein. Also disclosed are the use of combinations of inhibitor compounds or the use of an eNOS activator compound in combination with any one or more of the inhibitor compounds. Also disclosed are methods for inhibiting the pro-coagulant activity of thrombin using a Tie-1 or Tie-1 endodomain inhibitor compound or an EphA2 inhibitor compound. Methods for diagnosing and monitoring vascular inflammatory disorders or endothelial cell disorders that include the measurement of any of the polypeptides or nucleic acid molecules of the invention are also disclosed.

The present invention provides a composition that includes: (a) xanthophylls; (b) vitamin C; (c) vitamin E; (d) zinc; and (e) copper. The present invention also provides a method of treating macular degeneration in a human, inhibiting angiogenesis in a human, preventing impairment of the vision or for improving impaired vision of a human whose eye has drusen, and/or treating a disease associated with ocular neovascularitis in a human. The methods include administering to a human in need of such treatment an effective amount of the composition of the present invention.

The invention discloses a single-chain antibody of human source anti-alexin C3d molecules. A light chain and a heavy chain of the antibody have a unique CDR region; excellent antigen binding activityis realized; the affinity constant reaches 1.22*10<-7> mol/L. Biological distribution experiments prove that the anti-C3d single-chain antibody provided by the invention can be highly gathered in thearthritis positions after entering a mouse model with rheumatoid arthritis; the arthritis serious degree of the three ScFv treatment groups is obviously lower than that of a PBS group; the healing degree has the obvious dose dependency relationship; the result shows that the excellent anti-adhesion/ anti-inflammatory targeted inhibition effects are achieved. In the treatment process on MRL/lpr mice with lupus erythematosus, the anti-C3d single-chain antibody provided by the invention can obviously improve the survival rate of the mice; the symptoms of proteinuria, glomerular score, interstitial inflammation, vasculitis and crescent/necrosis and the like in the treatment group are obviously relieved. The result shows that the anti C3d single-chain antibody provided by the invention has excellent application prospects in the preparation of medicine for treating autoimmune diseases.

The invention belongs to a healthy protection wine, which is composed of notopterygium root, radix sileris, angelica, cassia twig, achyranthes, teasel root, wild celery, asarum, prepared rhizome of adhesive rehmannia, tuckahoe, radix codonopsitis, coix seed, qinjiu, hemlock parsley, eucommia bark, root of herbaceous peony, astragalus root, liquorice, lycopodium calvatum, Stringy Stonecrop Herb, Gambir Plant, pawpaw and xungufeng; and the above materials are smashed and dipped in high purity wine to prepare the healthy wine. The wine has functions of supplementing qi and nourishing Blood, removing rheumatism, strengthening bones and muscles, relieving convulsion, inducing diaphoresis, expelling wind and relieving convulsion, clearing away heat to stop liver, sumplementing qi and generating yang, strengthening exterior and reducing sweat, promoting urination and reducing swelling, strengthening the middle Burner and replenishing qi, promoting fluid and benefiting blood, activate yang converting qi, removing stasis and adjusting menstruation, activating articulation, nourishing liver and kidney, and cycling blood, and the wine can regulate the internal secretion from various reaspects; and improve radically human body unity and can supply nourishment reasonably; thus having special effect for curing the rheumatism and rheumatoid disease, lumbar disc herniation, arthritis, sciatica, vasculitis, impotence and cardiovascular and cerebrovascular disease.

Apparatus and methods for treating and monitoring conditions such as rhinitis are disclosed herein. The technology utilizes ultrasound scans to identify target treatment sites, and monitor the treatment of a patient undergoing a treatment. The treatment may be an ablation treatment of a nasal nerve, for example the PNN for the treatment of nasal conditions, such as rhinitis. The ultrasound scans are performed within the nasal cavity with an ultrasound probe or a combined ultrasound and ablation probe and may use Doppler, A-mode, B-mode, M-mode or other ultrasound and non-ultrasound modalities to detect and monitor the target treatment sites.

The invention relates to a method for the in vitro detection of vasculitis or the risk of developing vasculitis, including determining the presence and/or the amount of anti-endothelial cell antibodies (AECA) or anti-vascular smooth muscle cell (VSMC) antibodies in a biological sample from a patient.

A compound of formula (I) wherein R<1> and R<2> are as defined in the description, R<2> being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzeimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.

The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood.

The invention relates to an application of the fusion proteins FP1-FP8 of VEGF receptors on the treatment of the diseases relating to angiogenesis. The diseases relating to the angiogenesis includes autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, vasculitis, systemic sclerosis and other diseases caused by the angiogenesis such as bronchial asthma, obesity, nasal polyps, rhinitis, liver cirrhosis, endometriosis, uterine bleeding, warts, scars and ovarian cysts, etc.

The present invention relates to a medicament comprising the compound of formula (I)

wherein all symbols have the same meanings as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention is useful for the prevention and/or treatment of immune diseases such as various types of inflammation, autoimmune disease, allergic diseases, etc.; infection concerning inflammation or HIV infections (e.g. asthma, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis, etc.), organ transplantation rejection, immunosuppression, psoriasis, multiple sclerosis, optic neuritis, polymyalgia rheumatica syndrome, uveitis, vasculitis, human immunodeficiency virus infection (acquired immunodeficiency syndrome etc.), atopic dermatitis, urticaria, allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis, osteoarthritis, ischemic reperfusion injury, acute respiratory distress syndrome, shock accompanying bacteria infection, diabetes, cancer metastasis, atherosclerosis, etc.).

The invention relates to a medicine for treating vasculitis and particularly relates to a traditional Chinese medicinal composition for treating vasculitis, which is prepared by using plant traditional Chinese medicinal herbs as raw materials, and is characterized in that the active ingredients are prepared from the following raw material medicines by weight: 25 to 35 grams of Chinese angelica, 25 to 35 grams of astragalus, 20 to 30 grams of salvia miltiorrhiza bunge, 20 to 30 grams of dendrobium, 15 to 25 grams of safflower, 15 to 25 grams of Codonopsis pilosula, 10 to 20 grams of szechuan lovage rhizome, 10 to 20 grams of red paeony root, 10 to 20 grams of twotooth achyranthes root, 5 to 15 grams of peach kernel, 5 to 15 grams of frankincense, 5 to 15 grams of myrrh, and 3 to 8 grams of liquoric root. In the invention, the medicines are mixed to bring out the best in one another, the composition has the effects of enriching and activating blood, tonifying spleen and qi, tonifying lung, consolidating superficies, tonifying stomach, promoting fluid, promoting blood circulation, removing blood stasis, cooling blood, resoluting carbuncle, relieving restlessness, soothing the nerves, nourishing Yin, clearing heat, removing stasis and relieving pain, can address both symptoms and root causes without side and toxic effects and is more effective in treating vasculitis caused by blood stasis, the composition is simple and the price is low.

The invention relates to a traditional Chinese medicine composition for treating thromboangiitis obliterans and a preparation method thereof, belonging to a traditional Chinese medicine composition and a preparation method thereof and solving the problems of multiple components, difficult formation and high cost of the conventional traditional Chinese medicine composition for treating vasculitis. The traditional Chinese medicine composition is prepared by adopting the raw materials of astragalus root, the root of red-rooted salvia, cassia bark, Szechuan lovage rhizome, dangshen, figwort root, angelica sinensis, frankincense, suberect spatholobus stem, myth, liquorice and honeysuckle. The preparation method 1 comprises the steps of: weighting the raw materials; mixing the angelica sinensis, the Szechuan lovage rhizome and the cassia bark and adding water for soaking, extracting essential oil, recovering essential oil extract, mixing dregs of a decoction and a liquid medicine with the astragalus root, the dangshen, the figwort root, the suberect spatholobus stem, the liquorice and the honeysuckle and adding water for extracting; concentrating clear paste; wrapping by using beta-cyclodextrin; and adding a wrapped matter and the root of red-rooted salvia, the frankincense and the myrrh after crushed into fine powder into the clear paste to be stirred. The preparation method 2 comprises the steps of: weighting the raw materials, adding water for extracting and concentrating the clear paste. The traditional Chinese medicine composition has less medicine components, easy formation, small added amount of auxiliary materials, low cost, simple method and easy obtaining of the raw materials.

An intravenous injection for treating thrombotic vasculitis, cerebral infarction, coronary heart disease, hypertension, rheumatoid arehritis, etc is prepared from Chinese angelica root, sodium chloride and water for injection through preparing pieces, water extracting, alcohol extracting, resin filtering, proportioning, filtering, ultrasonic purifying and high-temp and high-pressure sterilizing. It has high curative effect.

A Chinese medicine in the form of treating vasculitis, phlebitis, phlebothrombosis, lymphangitis, Raynaud's disease, etc is prepared from 6 Chinese-medicinal materials including pangolin scales, red sage root, dahurian angelica root, Chinese angelica root, etc through decocting four of them twice, concentrating the decoction, mixing with the powder of others, drying, pulverizing, sieving and loading in capsules.

Genes whose expression is correlated with the presence of CIDP or vasculitic neuropathy are disclosed. Probes and sets of nucleic acids and proteins specific for these genes are described, as are molecular and immunological methods for aiding in the diagnosis of these disease conditions in a subject.

The invention provides a micro RNA group related to Th17 differentiation. The micro RNA group comprises micro RNA 4426, micro RNA 3615, micro RNA 106b, micro RNA 590 and micro RNA 573. The micro RNA changes remarkably in the Th17 differentiation process and can be used as Th17 control targets for preparing drugs for treating or preventing Th17-related diseases including lupus erythematosus, dermatomyositis, vasculitis, sicca syndromes, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, scleroderma, multiple sclerosis, malaria, solar dermatitis, eczema, leucoderma, psoriasis, atopic dermatitis, lichen planus, diabetes, coronary heart diseases, hyperlipemia and the like. The micro RNA group is sensitive to hydroxychloroquine intervention and can serve as a sensitive index for judgment of the clinical effect of hydroxychloroquine, and the micro RNA is convenient to test clinically and can be rapidly used for judging the clinical effect of hydroxychloroquine.

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing a SYK inhibitor, or a pharmaceutically acceptable salt thereof, and a antineoplastic or antiinflammatory agent for the treatment of inflammatory, autoimmune and cell proliferative diseases, such as allergic reaction, transplant rejection, rheumatoid arthritis (RA), lupus, multiple sclerosis (MS) or psoriasis undesired acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL) (including diffuse large B cell lymphoma (DLBCL)), mantle cell lymphoma, acute lymphocytic leukemia (ALL), follicular lymphoma, Burkitt's lymphoma, small Lymphocytic (SLL), Lymphoma, multiple myeloma, asthma, vasculitis, Idiopathic thrombocytopenic purpura (ITP), Heparin Induced Thrombocytopenia (HIT) and hemolytic anemia.

Genes whose expression is correlated with the presence of CIDP or vasculitic neuropathy are disclosed. Probes and sets of nucleic acids and proteins specific for these genes are described, as are molecular and immunological methods for aiding in the diagnosis of these disease conditions in a subject.

The invention discloses an auxiliary blood sugar decreasing composite containing tibetan medicine edgeworthia gardneri and a preparation method of the composite. The preparation method comprises the following step of proportioning edgeworthia gardneri ultra-fine powder or edgeworthia gardneri extractive with the following medicines in a weight ratio of (99:1)-(1:99), so that a composite can be obtained, wherein the medicines consist of one or more of the root of kudzu vine, the poria cocos, the fruit of Chinese wolfberry, the balsam pear, the pumpkin, the rhizoma polygonati, the Chinese yam, the American ginseng, the root of straight ladybell, the Jin Qianliu, the pollen, the rehmannia, the astragalus mongholicus and the burdock; the edgeworthia gardneri ultra-fine powder is obtained by means of ultrafine grinding; and the edgeworthia gardneri extractive is obtained by the repeated solvent extraction of the edgeworthia gardneri flower. According to the invention, the edgeworthia gardneri ultra-fine powder or the edgeworthia gardneri extractive and the medicinal and edible medicines are combined with one another to prepare the food or the health care product which is benefit for the diabetes mellitus, the coronary disease, the hypertension, the hyperlipidemia, the vasculitis, the angiitis and the like; and the paired observation shows that the food or the health care product can more powerfully restrain the alpha-glucosidase, can treat the diabetes mellitus, and can obviously control the blood sugar.

The present invention relates to a method for diagnosis of a disease selected from the group of diabetes, vasculitis, collagenosis, an inflammatory rheumatic disease and arteriosclerosis wherein, presence or absence of an anti-AT₁-receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT₁-receptor antibody is indicative of the disease. The invention further relates to the use of an inhibitor of an anti-AT₁-receptor antibody or an inhibitor of an AT₁-receptor for the production of a medicament as well as plasmapheresis of blood for the removal of anti-AT₁-receptor antibodies.